Facebook Linkedin RSS Twitter Youtube
Home 2021

Non-hodgkin lymphoma

‘Manufacturing-First Approach’ Pays Off for Cell Therapy Developer Artiva
Cancer

‘Manufacturing-First Approach’ Pays Off for Cell Therapy Developer Artiva

Top 10 Young Companies in the Money, 2019
A-Lists

Top 10 Young Companies in the Money, 2019

Catalent Agrees to Manufacture BeiGene’s Tyrosine Kinase Inhibitor for Lymphoma Therapy
Bioprocessing

Catalent Agrees to Manufacture BeiGene’s Tyrosine Kinase Inhibitor for Lymphoma Therapy

AstraZeneca Asthma Candidate Tralokinumab Fails Two Phase III Trials
Drug Discovery

AstraZeneca Asthma Candidate Tralokinumab Fails Two Phase III Trials

Debiopharm Pays $25M Upfront for ImmunoGen’s Phase II Stage ADC for NHL
Cancer

Debiopharm Pays $25M Upfront for ImmunoGen’s Phase II Stage ADC for NHL

EC Approves Actelion’s Topical Chlormethine Gel for MF-Type CTCL
Cancer

EC Approves Actelion’s Topical Chlormethine Gel for MF-Type CTCL

Roche/Chugai’s Alecensa Wins Conditional EC Approval for ALK-Positive NSCLC
Cancer

Roche/Chugai’s Alecensa Wins Conditional EC Approval for ALK-Positive NSCLC

Fosun, Daiichi Sankyo Ink Deals for Kite’s CAR T-Cell Therapy in China and Japan
Drug Discovery

Fosun, Daiichi Sankyo Ink Deals for Kite’s CAR T-Cell Therapy in China and Japan

Affimed and MD Anderson Combine NK Cells and Bispecific Abs for Cancer Therapy
Drug Discovery

Affimed and MD Anderson Combine NK Cells and Bispecific Abs for Cancer Therapy

As Kite Taxis for Takeoff, Another Flight Plan Emerges
Insights

As Kite Taxis for Takeoff, Another Flight Plan Emerges

1234...12Page 3 of 12
Copyright © 2025 Genetic Engineering & Biotechnology News. All Rights Reserved.